Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2520-1026
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cost-effectiveness of different treat-to-target strategies in rheumatoid arthritis: results from the DREAM registry ; volume:3 ; number:1 ; day:29 ; month:4 ; year:2019 ; pages:1-9 ; date:12.2019
BMC Rheumatology ; 3, Heft 1 (29.4.2019), 1-9, 12.2019
- Urheber
-
van de Laar, Celine J.
Oude Voshaar, Martijn A. H.
Vonkeman, Harald E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41927-019-0064-9
- URN
-
urn:nbn:de:101:1-2019051023431114316174
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- van de Laar, Celine J.
- Oude Voshaar, Martijn A. H.
- Vonkeman, Harald E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions
Au Clusters Treat Rheumatoid Arthritis with Uniquely Reversing Cartilage/Bone Destruction
Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry
Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry
Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry
Is Baricitinib Effective and Safe for Patients with Difficult-to-Treat Rheumatoid Arthritis? Comparative Data with the Rheumatoid Arthritis Group of Rheumatoid Arthritis Not Difficult to Treat
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions